PCC Rokita SA

WSE:PCR Rapporto sulle azioni

Cap. di mercato: zł1.4b

PCC Rokita Crescita futura

Future criteri di controllo 2/6

PCC Rokita prevede che gli utili e i ricavi cresceranno rispettivamente di 14.4% e 5.6% all'anno. Si prevede che l'EPS crescerà di 24.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 11.4% in 3 anni.

Informazioni chiave

14.4%

Tasso di crescita degli utili

24.9%

Tasso di crescita dell'EPS

Chemicals crescita degli utili21.8%
Tasso di crescita dei ricavi5.6%
Rendimento futuro del capitale proprio11.4%
Copertura analitica

Low

Ultimo aggiornamento15 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?

May 30
Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?

Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Aug 24
Is PCC Rokita (WSE:PCR) Using Too Much Debt?

PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 29
PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year

Is PCC Rokita (WSE:PCR) A Risky Investment?

Jan 18
Is PCC Rokita (WSE:PCR) A Risky Investment?

PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23

Apr 16
PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23

Why We Like The Returns At PCC Rokita (WSE:PCR)

Mar 19
Why We Like The Returns At PCC Rokita (WSE:PCR)

What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?

Jan 25
What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?

We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)

Sep 01
We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)

Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching

Jun 14
Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching

Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?

May 18
Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?

Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes

Apr 13
Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes

Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem

Mar 23
Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem

PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Mar 09
PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?

Feb 19
Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?

What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?

Feb 04
What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?

Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Jan 15
Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?

Dec 30
Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?

Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years

Dec 17
Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years

PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Dec 03
PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?

Nov 20
Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?

Previsioni di crescita degli utili e dei ricavi

WSE:PCR - Stime future degli analisti e dati finanziari passati (PLN Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20262,3781891733763
12/31/20252,2491221272783
12/31/20241,95290983022
9/30/20241,995121188335N/A
6/30/20242,048158212376N/A
3/31/20242,100144111310N/A
12/31/20232,388268296512N/A
9/30/20232,782473511736N/A
6/30/20233,072589623883N/A
3/31/20233,225692691941N/A
12/31/20223,143675563792N/A
9/30/20222,821569392621N/A
6/30/20222,560499383575N/A
3/31/20222,405472399553N/A
12/31/20212,203417380530N/A
9/30/20212,027294328468N/A
6/30/20211,827247267389N/A
3/31/20211,597171200342N/A
12/31/20201,476117195366N/A
9/30/20201,41473149340N/A
6/30/20201,46182136357N/A
3/31/20201,48272123355N/A
12/31/20191,4929377310N/A
9/30/20191,51314581316N/A
6/30/20191,50316055295N/A
3/31/20191,51220182356N/A
12/31/20181,49022741287N/A
9/30/20181,44524318254N/A
6/30/20181,378215N/A220N/A
3/31/20181,345213N/A181N/A
12/31/20171,286182N/A204N/A
9/30/20171,234208N/A264N/A
6/30/20171,187213N/A264N/A
3/31/20171,129207N/A259N/A
12/31/20161,107203N/A263N/A
9/30/20161,084135N/A220N/A
6/30/20161,097131N/A187N/A
3/31/20161,077110N/A161N/A
12/31/20151,04985N/A149N/A
9/30/20151,05373N/A123N/A
6/30/20151,06262N/A130N/A
3/31/20151,08362N/A119N/A
12/31/20141,09371N/A165N/A
9/30/20141,06658N/A117N/A
6/30/20141,04148N/A96N/A
3/31/20141,08552N/A98N/A
12/31/20131,10158N/A104N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di PCR ( 14.4% all'anno) è superiore al tasso di risparmio ( 4.1% ).

Guadagni vs Mercato: Si prevede che gli utili di PCR ( 14.4% all'anno) cresceranno più lentamente rispetto al mercato Polish ( 15.6% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di PCR cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di PCR ( 5.6% all'anno) crescerà più rapidamente del mercato Polish ( 4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di PCR ( 5.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di PCR sarà basso tra 3 anni ( 11.4 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y